By Colin Kellaher

Regeneron Pharmaceuticals Inc. on Wednesday said the U.S. Food and Drug Administration accepted for review its application for expanded use of the cancer drug Libtayo, in combination with chemotherapy, as first-line treatment in advanced non-small cell lung cancer.

The Tarrytown, N.Y., biotechnology company, which is developing and commercializing Libtayo with France's Sanofi SA under a global collaboration agreement, said the agency set a target action date of Sept. 19.

The companies also recently filed for European regulatory approval in the indication.

Regeneron said the application is supported by results from a randomized, multicenter Phase 3 study that was stopped early after the combination showed a significant overall survival improvement compared to chemotherapy alone.

Non-small cell lung cancer accounts for roughly 84% of all lung cancer, the leading cause of cancer death worldwide, Regeneron said.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

January 19, 2022 07:37 ET (12:37 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.
Grafico Azioni Sanofi (EU:SAN)
Storico
Da Giu 2024 a Lug 2024 Clicca qui per i Grafici di Sanofi
Grafico Azioni Sanofi (EU:SAN)
Storico
Da Lug 2023 a Lug 2024 Clicca qui per i Grafici di Sanofi